GLUCAGON ANALOGUES
First Claim
Patent Images
1. A compound having the formula I:
-
R1—
Z—
R2
(I)or a pharmaceutically acceptable salt or solvate thereof;
whereinR1 is hydrogen, C1-4 alkyl, acetyl, formyl, benzoyl or trifluoroacetyl;
R2 is OH or NH2; and
Z is an amino acid sequence deriving from the sequence of formula Ia;
His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Glu-Asn-Thr
(Ia)and further comprising at least four amino acid substitutions or deletions that are only at sequence positions selected from 2, 3, 4, 9, 10, 15, 16, 17, 20, 21, 24, 28 and 29, as follows;
X2 is selected from Aib and Ala;
X3 is selected from His, Pro, Dab(Ac), Dap(Ac) and Gln(Me);
X4 is DAla;
X9 is Glu;
X10 is selected from Val, Leu, N-Me-Tyr and N-Me-DTyr;
X15 is Glu;
X16 is selected from Aib, Lys, Glu, Leu, Val, DVal, Phe, His, Arg, Pro, DPro, N-Me-Ser and N-Me-DSer;
X17 is selected from Ala and Ser;
X20 is selected from Glu and Lys;
X21 is selected from Glu, Lys and Ser;
X24 is selected from Lys, Ser, Glu and Ala;
X28 is selected from Ser and Lys, and Glu, or is absent;
X29 is selected from Ser and Ala, or is absent;
with the proviso that Z is not selected from;
3 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to glucagon analogues and their medical use, for example in the treatment of hypoglycaemia. In particular, the present invention relates to stable glucagon analogues suitable for use in a liquid formulation.
18 Citations
59 Claims
-
1. A compound having the formula I:
-
R1—
Z—
R2
(I)or a pharmaceutically acceptable salt or solvate thereof; wherein R1 is hydrogen, C1-4 alkyl, acetyl, formyl, benzoyl or trifluoroacetyl; R2 is OH or NH2; and Z is an amino acid sequence deriving from the sequence of formula Ia;
His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Glu-Asn-Thr
(Ia)and further comprising at least four amino acid substitutions or deletions that are only at sequence positions selected from 2, 3, 4, 9, 10, 15, 16, 17, 20, 21, 24, 28 and 29, as follows; X2 is selected from Aib and Ala; X3 is selected from His, Pro, Dab(Ac), Dap(Ac) and Gln(Me); X4 is DAla; X9 is Glu; X10 is selected from Val, Leu, N-Me-Tyr and N-Me-DTyr; X15 is Glu; X16 is selected from Aib, Lys, Glu, Leu, Val, DVal, Phe, His, Arg, Pro, DPro, N-Me-Ser and N-Me-DSer; X17 is selected from Ala and Ser; X20 is selected from Glu and Lys; X21 is selected from Glu, Lys and Ser; X24 is selected from Lys, Ser, Glu and Ala; X28 is selected from Ser and Lys, and Glu, or is absent; X29 is selected from Ser and Ala, or is absent;
with the proviso that Z is not selected from; - View Dependent Claims (3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)
-
-
2. A compound having the formula I:
-
R1—
Z—
R2
(I)or a pharmaceutically acceptable salt or solvate thereof; wherein R1 is hydrogen, C1-4 alkyl, acetyl, formyl, benzoyl or trifluoroacetyl; R2 is OH or NH2; and Z is an amino acid sequence deriving from the sequence of formula Ia;
His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Glu-Asn-Thr
(Ia)and further comprising at least four amino acid substitutions or deletions that are only at sequence positions (designated as X) selected from 2, 3, 9, 10, 15, 16, 17, 20, 21, 24, 28 and 29, as follows; X2 is selected from Aib and Ala; X3 is selected from His and Pro; X9 is Glu; X10 is selected from N-Me-Tyr and N-Me-DTyr; X15 is Glu; X16 is selected from Aib, Lys, Glu, Leu, Val, DVal, Phe, His, Arg, Pro, DPro, N-Me-Ser and N-Me-DSer; X17 is selected from Ala and Ser; X20 is selected from Glu and Lys; X21 is selected from Glu, Lys and Ser; X24 is selected from Lys, Ser, Glu and Ala; X28 is selected from Ser and Lys, or is absent; X29 is selected from Ser and Ala, or is absent; with the proviso that Z is not selected from;
-
-
48. An expression vector comprising a nucleic acid construct according to claim 48.
Specification